ID: ALA4525199

Max Phase: Preclinical

Molecular Formula: C20H16FN7O

Molecular Weight: 389.39

Molecule Type: Unknown

Representations

Canonical SMILES:  C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2ccnc2C(N)=N1

Standard InChI:  InChI=1S/C20H16FN7O/c1-20(11-28-7-6-24-18(28)17(23)27-20)14-8-13(3-4-15(14)21)26-19(29)16-5-2-12(9-22)10-25-16/h2-8,10H,11H2,1H3,(H2,23,27)(H,26,29)/t20-/m0/s1

Standard InChI Key:  PURBTYQRCRLUGF-FQEVSTJZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.39

Molecular Weight (Monoisotopic): 389.1400

AlogP: 2.18

#Rotatable Bonds: 3

Polar Surface Area: 121.98

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.93

CX Basic pKa: 6.39

CX LogP: 1.75

CX LogD: 1.71

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.71

Np Likeness Score: -1.69

References

1. Oehlrich D, Peschiulli A, Tresadern G, Van Gool M, Vega JA, De Lucas AI, Alonso de Diego SA, Prokopcova H, Austin N, Van Brandt S, Surkyn M, De Cleyn M, Vos A, Rombouts FJR, Macdonald G, Moechars D, Gijsen HJM, Trabanco AA..  (2019)  Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.,  10  (8): [PMID:31413800] [10.1021/acsmedchemlett.9b00181]

2. Peschiulli A, Oehlrich D, Van Gool M, Austin N, Van Brandt S, Surkyn M, De Cleyn M, Vos A, Tresadern G, Rombouts FJR, Macdonald GJ, Moechars D, Trabanco AA, Gijsen HJM..  (2022)  A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo.,  13  (1.0): [PMID:35059126] [10.1021/acsmedchemlett.1c00445]

Source

Source(1):

• Scientific Literature